LLY Eli Lilly
- Official Name: ELI LILLY AND COMPANY
- Headquarters: Lilly Corporate Ctr, Drop Code 1094, INDIANAPOLIS, IN, 46285 US
- CEO: David A. Ricks
- Website: lilly.com
- Key Investor: PNC FINANCIAL SERVICES GROUP, INC. | 10.68%
- Dedicated Investor: LILLY ENDOWMENT INC | 100%
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-15 | 1 | Won by 1.485 | 0.622 - (0.863) | ||
| 2025-07-22 | 2 | Lost by 1.727 | 1.457 - 3.184 | ||
| 2025-07-29 | 3 | Lost by 4.303 | (2.272) - 2.031 | ||
| 2025-07-29 | 2R | Lost by 6.678 | (5.321) - 1.357 | ||
| 2025-08-05 | 4 | Won by 2.977 | 2.823 - (0.154) | ||
| 2025-08-07 | 1R | Lost by 13.781 | (10.430) - 3.351 | ||
| 2025-08-12 | 5 | Won by 0.443 | 0.329 - (0.114) | ||
| 2025-08-19 | 6 | Won by 8.814 TOTW | 11.298 - 2.484 | ||
| 2025-08-26 | 7 | Won by 1.644 TOTW | 4.545 - 2.901 | ||
| 2025-09-02 | 8 | Lost by 3.542 | (0.113) - 3.429 | ||
| 2025-09-03 | 1R | Won by 1.312 | 0.243 - (1.069) | ||
| 2025-09-09 | 9 | Won by 2.208 | 2.208 - 0.000 | ||
| 2025-09-16 | 10 | Won by 1.163 | 2.318 - 1.155 | ||
| 2025-09-17 | 2R | Won by 0.260 | (0.577) - (0.837) | ||
| 2025-09-23 | 11 | Lost by 2.279 | (2.638) - (0.359) | ||
| 2025-09-30 | 12 | Won by 2.733 | 2.132 - (0.601) | ||
| 2025-10-01 | QF | Won by 7.240 | 7.918 - 0.678 | ||
| 2025-10-07 | 13 | Won by 10.569 TOTW | 9.513 - (1.056) | ||
| 2025-10-14 | 14 | Lost by 1.954 | (3.845) - (1.891) | ||
| 2025-10-15 | SF | Won by 0.503 | 1.869 - 1.366 | ||
| 2025-10-21 | 15 | Lost by 0.029 | (1.548) - (1.519) | ||
| 2025-10-22 | F | Won by 1.225 | 1.678 - 0.453 |
Latest News
Lilly confirms date and conference call for third-quarter 2026 financial results announcement
Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2026 financial results on October 29, 2026. Lilly will also conduct a conference cal...
Where Could Johnson & Johnson's Next Growth Come From?
Johnson & Johnson (JNJ) stock trades at 29.1 times its earnings over the past twelve months, compared with 22.7 for the S&P 500. Investors pay...
New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
New data analyses from Eli Lilly and Company (NYSE: LLY) show patients with moderately to severely active ulcerative colitis (UC) and Crohn's dis...
Dow Jones Futures Rise, But AI Sell-Off Continues On Anthropic News; Taiwan Semiconductor Earnings Strong
Dow Jones futures rose but the AI sell-off continues following Anthropic revenue figures. Taiwan Semiconductor earnings beat.
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the on...
Lilly Reports Omvoh Achieved Multiple Treatment Goals Simultaneously At One Year In IBD Studies
In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a novel composite ou...
Stock Market Today: Hot Inflation and a Neocloud Shakeout Sink the Nasdaq
Hotter September inflation revived Fed hike bets and a Gartner warning crushed AI neoclouds. Pharma caught a bid, BlackRock hit a record, BofA got fin...
Adlai Nortye Group enters Clinical Trial Collaboration And Supply Agreements With Eli Lilly And Merck KGaA For The ERBITUX Anti-EGFR Antibody
These agreements will support Adlai Nortye’s ongoing Phase I trial evaluating AN4035, a pan-RAS(ON) inhibitor-based ADC, both as monotherapy and in ...
Polen Focus Growth Portfolio Q3 2026 Portfolio Update
In Q3 2026, we initiated new positions in Adyen, ASML, Quanta Services, and Seagate Technology, while selling MSCI and Rollins. Read more here.
Walmart to increase employee benefits with new initiative for 2027
The retailer is making a big bet on its 1.6 million U.S. workers.
Why Eli Lilly Became Wall Street’s Safe Haven on a Hot CPI Day
Eli Lilly (LLY:NYSE) stock rose roughly 4% on Wednesday, October 14, joining a broad rally in healthcare stocks. No major Lilly news drove it.
How Much Downside Is Left In Liquidia Stock?
Over the past month, shares of Liquidia (LQDA) have lost 59%, even as the S&P 500 gained 2.5%. Reuters reported that the stock dropped nearly 50% ...
Dow Jones Futures: Techs Fall On Anthropic News After Dell, AMD, CoreWeave Dive In AI-Led Sell-Off
Tech futures fall as Anthropic revenue jumps, but not enough? The stock market tested key levels on AI fears. Taiwan Semiconductor earnings loom.
Eli Lilly (LLY) Stock Looks Undervalued As Its 404% Run Continues
Eli Lilly’s stock has become one of the most closely watched pharmaceuticals on the market, and at around US$1,166 per share the question for invest...
Dow Jones Futures: Dell, AMD, CoreWeave Lead Market Sell-Off On AI Fears; Taiwan Semiconductor Due
The stock market tested key levels on Fed and AI fears. Dell, AMD, CoreWeave were big losers. Taiwan Semiconductor earnings loom.
Top S&P500 movers in Wednesday's session
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wed...
Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide
Stocks skidded midweek as the Nasdaq Composite dropped 449 points, or 1.65%, to 26,755.24, pulling its weekly loss to 2.23%. The S&P 500 fell 1.10...
Lilly, Merck, AbbVie Stocks Surge. Why Healthcare Is Rallying Today.
Shares of Lilly, the world’s largest pharmaceutical company by market value, rallied above their 50-day moving average to mark their best level sinc...
Roche Expands Obesity Pipeline With Rona's RNAi Candidate
RHHBY expands its obesity pipeline with a novel RNAi candidate targeting ALK7, while advancing enicepatide and other late-stage drugs to strengthen it...
Exploring the top movers within the S&P500 index during today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wed...
QUICK SPARK: This New ETF Goes Beyond Eli Lilly, Novo Nordisk and Targets the Peptide Boom
REX launches the PEPT ETF, offering exposure beyond Eli Lilly and Novo Nordisk as the GLP-1 market heads toward $200 billion by 2030.
Viking’s Key Obesity Pill Enters Phase 3 Trial – Here’s What Investors Need To Know
Viking is set to begin two simultaneous studies of VK2735 in a Phase 3 trial after Phase 2 showed weight reductions of up to 12.2% after 13 weeks.
The Open Question Under Johnson & Johnson Stock's Price
Johnson & Johnson (JNJ) has introduced several new drugs recently, and current buyers of its stock may be betting on their commercial success. The...
Bet on These Healthcare ETFs to Benefit From the Aging US Population
With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-relat...
Eli Lilly and Company Earnings Preview: What to Expect
Eli Lilly and Company is set to report its Q3 results soon, with analysts anticipating single-digit EPS growth alongside continued earnings growth.
Nasdaq 100 Drops 1% on Hot CPI, SOXX Falls 7th Day: Stock Market Today
The Nasdaq 100 fell 1% by midday Wednesday after September CPI topped forecasts, pushing Treasury yields and rate-hike bets higher.
J&J Beat and Raised. The Stock Fell Anyway. Here’s What the Target Says
Johnson and Johnson crushed earnings, raised guidance, and still watched its stock crater nearly 6% in a single session. Understanding what spooked in...
8 Of 11 Sectors Fall Wednesday As Defensives Lead
Three sectors are higher and eight are lower in Wednesday's regular session, with defensive sectors holding the top three positions. The leade...
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, acco...
Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb recovered to $7.1B in net income while Eli Lilly more than doubled profits to $20.6B, a stark contrast in momentum that reshapes ...
How Early Taltz and Zepbound Biomarker Synergies At Eli Lilly (LLY) Have Changed Its Investment Story
Eli Lilly recently reported exploratory Phase 3b data from the TOGETHER-PsO trial showing that combining Taltz with Zepbound in adults with moderate-t...
Here's Why Eli Lilly (LLY) Fell More Than Broader Market
Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -1.04% change compared to its last close.
3 Dividend Growth Stocks That Have Doubled Their Payouts in 5 Years
These stocks have rewarded their shareholders with significant dividend increases in recent years and are likely to continue doing so in the future.
Sangamo Therapeutics Launches Auction Process for Clinical-Stage Chronic Neuropathic Pain Program
Auction process initiated for ST-503 program for chronic neuropathic pain, expected to be completed in fourth quarter of 2026 Previously announced ass...
What Is Eli Lilly Stock's Biggest Opportunity?
Investors are currently valuing Eli Lilly (LLY) stock at a premium, with shares priced at 39.5 times earnings compared with 21.9 for the S&P 500. ...
The Five Largest Holdings in the RANK ETF After Its Latest Rebalance
The Defiance KSM TipRanks Analyst ETF (RANK) has completed its latest quarterly reconstitution and rebalance, which took effect after the close on Sep...
Sector Update: Healthcare Stocks Fall Tuesday Afternoon
Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index falling 1.1% and the
Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial
Prelude expects patient enrollment to begin in Q4 2026, starting with monotherapy dose escalation before advancing to combination cohorts.
Prediction: Eli Lilly Could Have More Room to Grow Than Its Valuation Suggests
Eli Lilly trades at a premium multiple, yet its revenue growth dwarfs every major pharma peer by a wide margin. Whether that gap justifies buying shar...
Walmart to cover GLP-1s, insulin at no cost for workers in benefits push - report
Investing.com -- Walmart Inc (NASDAQ:WMT) plans to cover more than 250 prescription medications at no cost for its workforce, according to a staff mem...
How to Play TRXB Stock After the TRex Bio IPO
TRex Bio has Eli Lilly’s backing, but its IPO didn't really impress Wall Street. Is this biotech newcomer worth a shot, or should investors let...
Eli Lilly Reports Earnings on Oct. 29. Here's Why the Retatrutide Story Matters More Than the Quarter.
Eli Lilly's next big growth driver could be bigger than Zepbound.
Walmart to cover some GLP-1s, inhalers and insulin for employees at no cost as it expands benefits
Walmart will offer Novo's Ozempic and Lilly's Mounjaro without charge for people with Type 2 diabetes after a new prior authorization.
Why A Biotech M&A Wave May Hit This Winter
Biotech stocks have slumped from their August highs. But experts say renewed M&A, likely coming, could catalyze them.
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
Combination cohorts are part of Prelude’s Phase 1 trial evaluating PRT13722 in patients with HR+/HER2- breast cancer, on track to initiate enrollmen...
Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued.
This pharma stock has climbed in the triple digits in recent years.
U.K. Medicines And Healthcare Products Regulatory Agency Authorizes Eli Lilly's Onswik For Adults With Type 2 Diabetes
https://www.gov.uk/government/news/mhra-authorises-onswik-insulin-efsitora-alfa-for-adults-with-type-2-diabetes
Prelude Therapeutics Enters Clinical Trial Collaboration And Supply Agreement With Eli Lilly For Supply Of Its CDK4/6 Kinase Inhibitor, Abemaciclib And Its Oral Estrogen Receptor Antagonist Imlunestrant
The agreement supports the evaluation of Prelude’s clinical development candidate PRT13722, an oral KAT6A selective degrader, in combinations with a...
Will Eli Lilly Do a Stock Split Before the End of 2026?
Eli Lilly's stock price is comfortably above $1,000, and management could easily justify doing a stock split.
AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie trades at a 40% valuation discount but faces revenue concentration risk, while Eli Lilly's cardiometabolic dominance commands a premium.
Biogen (BIIB) Stock Is Up, What You Need To Know
Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.5% in the pre-market session after JPMorgan upgraded the stock to Overweight from Neutral with...
Sector Update: Healthcare Stocks Rise Late Afternoon
Healthcare stocks rose late Monday afternoon, with the NYSE Healthcare Index and the State Street He
Pharma’s manufacturing boom has a workforce problem
Drugmakers are pouring billions into U.S. production, but building enough plants won’t matter without enough skilled workers to run them.
4 Healthcare Stocks Worth Owning for the Next Decade
Two healthcare stocks that are leading their niches, and two that investors aren't giving enough credit to in the same niches.
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
NVO's 11% slide in a month reflects intensifying LLY competition, pricing pressure and a lack of near-term growth visibility despite its long-ter...
2 S&P 500 Stocks to Own for Decades and 1 We Find Risky
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face s...
Eli Lilly (LLY) Phase 3b Win Connects Psoriasis And Obesity Treatment
Eli Lilly (NYSE: LLY) reported new Phase 3b data on a combined Taltz and Zepbound regimen for adults with plaque psoriasis and obesity. The study link...
Will Skyrizi & Rinvoq Drive AbbVie's Top-Line Growth in Q3?
ABBV's Skyrizi and Rinvoq are expected to drive Q3 growth, offset Humira's ongoing decline and face rising competition in the immunology mar...
Lilly is fighting a black market for its new obesity drug even before it launches
The large pharma’s promising new candidate retatrutide is still in the clinic. But Lilly is already fighting a web of illicit sellers for the drug o...
This Drug Combination for Eli Lilly Generated Significantly More Weight Loss Than Just Zepbound, but Discontinuation Rates Were Also Far Higher. Here's What This Could Mean for the Stock
Eli Lilly isn't content with the success of its current GLP-1 drugs; it's on the hunt for even better weight loss solutions.
Eli Lilly Likely to Raise Revenue Outlook Amid Strong Diabetes, Weight-Loss Drug Sales, RBC Says
Eli Lilly (LLY) is likely to raise its full-year revenue outlook as third-quarter sales momentum in
Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock?
PFE moves above its 50-day SMA as newer drugs, oncology and obesity treatments fuel growth prospects, but declining COVID sales and patent expirations...
JPMorgan gets bullish on Biogen ahead of 2027 catalysts
Investing.com -- JPMorgan lifted its rating for Biogen to Overweight from Neutral on Monday, pointing to a stronger run of clinical catalysts in 2027 ...
Prediction: AbbVie’s Next Billion-Dollar Opportunity Is Taking Shape
Skyrizi and Rinvoq are growing fast, a blockbuster acquisition just closed, and the FDA handed AbbVie a fresh approval, yet the stock sits just shy of...
Lilly reports Phase IIIb data on Taltz and Zepbound combination
By week 36, dual therapy shifted 482 proteins and 467 genes, compared with 140 proteins and 16 genes.
RBC Capital Reiterates Outperform on Eli Lilly, Maintains $1500 Price Target
RBC Capital analyst Trung Huynh reiterates Eli Lilly (NYSE:LLY) with a Outperform and maintains $1500 price target.
Eli Lilly Stock Has Pulled Back 8%. History Says This Is What Happens Next.
Lilly's recent retreat isn't a sign of a broken investment thesis.
Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'
Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.
SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH
The ASH meeting runs Dec. 12-Dec. 15 in New Orleans. Sellas is listed at Booth 138, and more than 275 exhibitors are expected.
Top 50 High-Quality Dividend Growth Stocks For October 2026
Track 50 top dividend growth stocks: AMAT, DHI & HD climb as valuations shift.
Veeva Systems’ (VEEV) Comeback Gets Jim Cramer Talking
During the October 7 episode of Mad Money, Jim Cramer discussed Veeva Systems Inc. (NYSE:VEEV) as an example of a software business that had recovered...